Kingsoft Cloud Holdings Limited vs BIO-TECHNE Corp — how do they compare? Kingsoft Cloud Holdings Limited trades at $9.26 (market cap $2.71B), while BIO-TECHNE Corp trades at $72.47 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 4.2× Kingsoft Cloud Holdings Limited's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Kingsoft Cloud Holdings Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kingsoft Cloud Holdings Limited for 12 Days and BIO-TECHNE Corp for 64 Days on average.
| KC | TECH | |
|---|---|---|
Market Cap | $2.71B | $11.36B |
Volume | 1,993,765 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $18.21 | $72.61 |
52-Week Low | $8.58 | $43.31 |
Typical Hold Time | 12 Days | 64 Days |
Enterprise Value | $3.03B | $11.39B |
Dividend Yield | — | 0.44% |
Signals from Pluang's Aura AI — not financial advice
Kingsoft Cloud (KC) trades at $9.26, up 0.27% with bearish technical signals but strong analyst support. The company shows improving fundamentals with Q2 2026 revenue growth of 30.8% year-over-year and three consecutive earnings beats. While still reporting net losses, gross margins improved significantly and AI cloud services are emerging as a key growth driver, with billings surging 82% year-over-year.
KC presents a compelling turnaround story with 70% analyst buy ratings and 60% upside potential, though risks include persistent losses, competitive pressures, and technical weakness. The AI cloud partnership with Xiaomi positions the stock for growth, but investors should weigh the fundamental improvements against the current bearish technical setup.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →